An interventional study of MSCopilot Flower mobile application in Multiple Sclerosis, sponsored by Ad scientiam. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Ad scientiam · Not applicable, Interventional, and Other
This US multicenter, prospective cohort study aims to evaluate how MSCopilot can be seamlessly integrated into the current care pathway and identify potential optimizations to enhance its impact on both MS patients and clinicians, facilitating broader implementation. Specifically, the study will assess:
3,264 studies on the registry are indexed under Multiple Sclerosis; 659 are open to participants now.
This study's enrollment of 62 is above the median of 50 across 2,201 interventional studies indexed under Multiple Sclerosis.
Browse Multiple Sclerosis studies →Ad scientiam is the lead sponsor of 14 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
For patients
For HCPs:
Exclusion Criteria (for patients):
Early termination criteria (for patients):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: MSCopilot Flower mobile application
MSCopilot Flower includes active tests for walking, cognition, dexterity and vision, and e-questionnaires related to fatigue and Anxiety
To assess the ease of integrating the MSCopilot dashboard into clinical workflows for neurologists and the ease of use at home for patients with multiple sclerosis.
Descriptive analysis and acceptance criteria of a minimum score of \>2/4 on neurologists' questionnaires regarding the ease of integrating the MSCopilot dashboard into clinical workflows Descriptive analysis and acceptance criteria of a minimum score of \>2/4 on patients' questionnaires regarding the ease of use of MSCopilot at home
Time frame: For neurologists: Day 180 (+/- 30 days) and for patients: Day 1, Day 90 and Day 180 (+/- 30 days)
To assess the integration of MSCopilot dashboard and application into routine clinical practice as well as perceived value for both HCPs and patients.
Descriptive analysis of neurologists' questionnaires, to be completed after each investigator's last visit, regarding the Health Care Profesionnals (HCPs) dashboard Descriptive analysis and acceptance criteria of a minimum score of \>2/4 for each item, of neurologists' questionnaires after the last visit on the HCPs dashboard Descriptive analysis of patients' questionnaires after the last visit regarding MSCopilot app and dashboard use by the HCPs. Descriptive analysis and acceptance criteria of a minimum score of \>2/4 for each item in patients' questionnaires, to be completed after the follow-up visit, regarding MSCopilot application and dashboard use by HCPs
Time frame: At Day 180 ± 30days
To assess patients' ability to use MSCopilot at home without supervision.
Descriptive analysis of patient questionnaires Acceptance criteria of a minimum of \>2/4 for each item, of patient questionnaires
Time frame: Day 1 (+/- 30 days)
To assess patients' ability to use MSCopilot at home without supervision.
Descriptive analysis of patient questionnaires at mid-study Descriptive analysis and acceptance criteria of a minimum score of \>2/4 for each item, of patient questionnaires at mid-study
Time frame: Day 90 (+/-30 days)
To assess the need for patient support when using MSCopilot at home
Descriptive analysis of nurses or medical assistants' questionnaires (if applicable) Descriptive analysis and acceptance criteria of a minimum score of \>2/4 for each item, of nurses or medical assistants' questionnaires (if applicable)
Time frame: Day 180 (+/-30 days)
To assess patient adherence to MSCopilot use in routine clinical practice.
Descriptive analysis of the mobile application's adherence data, including: Number of performed tests, Number of performed sessions, Number of completed questionnaires.
Time frame: Day 1 to Day 180 (+/-30 days)
To assess user behavior based on usage analytics data from the MSCopilot mobile app and the dashboard.
Quantitative analysis of real-world utilization patterns of the MSCopilot mobile app through analytics data Quantitative analysis of real-world utilization patterns of the HCPs dashboard through analytics data
Time frame: Day 1 to Day 180 (+/-30 days)
To assess the effectiveness of HCPs onboarding/training in ensuring successful patient onboarding.
Descriptive analysis of HCPs (neurologists) questionnaires Descriptive analysis and acceptance criteria of a minimum score of \>2/4 for each item, of HCPs (neurologists) questionnaires
Time frame: At the end of inclusion period (90 days)
To assess the effectiveness of HCPs onboarding/training in ensuring successful patient onboarding.
Descriptive analysis of patient questionnaires Descriptive analysis and acceptance criteria of a minimum score of \>2/4 for each item, of patient questionnaires
Time frame: After patient inclusion visit (90 days)
To assess the adequacy of the onboarding/training process for HCPs, including neurologists, nurses, and medical assistants, focusing on clarity, satisfaction, and confidence in using MSCopilot
Descriptive analysis of HCPs questionnaires post-onboarding/training session Descriptive analysis and acceptance criteria of a minimum score of \>2/4 for each item in HCPs questionnaires post-onboarding/training
Time frame: After onboarding/training session (Day 0)
To assess the variances in user behavior and adherence to MSCopilot use according to socio-demographic factors and EDSS scores.
Descriptive analysis of how socio-demographic factors and EDSS scores affect patient behavior and adherence to MSCopilot mobile application.
Time frame: Day 1 to Day 180 (+/-30 days)
To assess the variances in user behavior and adherence to MSCopilot use according to socio-demographic factors and EDSS scores.
Descriptive analysis of how HCPs socio-demographic factors affect their behavior toward MSCopilot dashboard.
Time frame: Day 1 to Day 180 (+/-30 days)
Ran from Aug 2025 to primary completion in Apr 2026, 8 months.
Of 847 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 43. This study's 8 months is below that.
Counting every sponsor, half of 869 studies reached it within 21 months; a quarter within 9 and three quarters within 43.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Mar 2026 → Apr 2026 and completion Mar 2026 → Apr 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ad scientiam